Compare Vanguard Ultra Short Bond ETF (VUSB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Ultra Short Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Ultra Short Bond ETF trades at $49.6, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc pays a 1.02% dividend while Vanguard Ultra Short Bond ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| VUSB | ZBH | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $50.03 | $104.26 |
52-Week Low | $49.55 | $79.58 |
Market Cap | — | $17.97B |
Enterprise Value | — | $25.04B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VUSB trades at $49.595 with minimal daily movement, showing a slight decline of 0.01%. The technical picture is bearish with moving averages signaling selling pressure, though oscillators suggest potential short-term recovery. Recent dividend distributions of $0.17-0.18 per share demonstrate consistent income generation. Market sentiment is influenced by Federal Reserve interest rate expectations favoring short-term bonds.
The outlook remains cautious with bearish technical indicators offset by positive sentiment around short-term bond strategies. Investment opportunity lies in the ETF's defensive positioning amid potential rate hikes, while risks include interest rate sensitivity and market volatility. The stock presents a conservative income play in uncertain monetary policy environments.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
